Tag Archives: blood sugar

Transatlantic Disagreements on Diabetes

Not surprisingly, the Avandia news was the big buzz at the meeting of the European Association for the Study of Diabetes (EASD) in Stockholm. Attendees I spoke with expressed surprise that although the U.S. Food and Drug Administration and the European Medicines Agency had made announcements on same day, their decisions were different: The EMA had suspended Avandia entirely from the European market while the FDA decided to keep it on the U.S. market with tight restrictions.

How could the European and American agencies have reviewed the same data yet come to different conclusions regarding risk/benefit? And which decision was right? There was much speculation and debate in the hallways at EASD.

European Union flag photo by openDemocracy via Flickr Creative Commons

Simultaneously, another transatlantic debate was taking place at the meeting.  This one, though less likely to make headlines, also has major implications for clinical practice worldwide.

Back in January 2010, the American Diabetes Association recommended the use of hemoglobin A1c for diagnosing diabetes, listing convenience and stability of the test among the advantages. The move was controversial, with many scientists citing data suggesting that sizable proportions of people with diabetes will be missed by using that test rather than either fasting glucose or an oral glucose tolerance test (OGTT), considered the gold standard.

At the EASD meeting, investigators from the U.K., Spain, Norway, France, Portugal, and the Republic of Korea presented data showing a lack of correlation between the tests, and either advised against or at least recommended caution in the use of A1c as a diagnostic.

Prof. George Alberti summarized an expert committee’s recommendation to the World Health Organization that glucose testing should remain the preferred diagnostic method, with A1c as an alternative provided that certain conditions are met. Both the WHO and the EASD are expected to issue positions soon.

American Flag photo by ayblazerman via Flickr Creative Commons

I asked Dr. M. Sue Kirkman, clinical affairs vice president at ADA, to comment. She said that the ADA had been aware of data showing that the A1c may be less sensitive and therefore would identify fewer people with diabetes than does the fasting glucose, which in turn detects fewer cases than does the OGTT.

She noted that the ADA didn’t advise against glucose tests. “If people want to use glucose tests, they certainly can. But the reality is that a quarter of people with type 2 diabetes in the U.S. are undiagnosed. If you have a test that doesn’t require fasting, that you do when the patient’s in your office—especially in populations with less access to medical care—we think in the real world you can actually diagnose more people.”

While there’s disagreement over diagnostics, at least there’s one point of agreement: Few if any of those patients will be treated with Avandia.

—Miriam E. Tucker (@MiriamETucker on Twitter)


1 Comment

Filed under Cardiovascular Medicine, Drug And Device Safety, Endocrinology, Diabetes, and Metabolism, Family Medicine, IMNG, Internal Medicine, Primary care

Glycemic targets: How low to go?

Photo by Uwe Hermann under a Creative Commons license.

Photo by Uwe Hermann under a Creative Commons license.

From the 2009 UCSF Diabetes Update and Advances in Endocrinology and Metabolism meeting.

Some recent reports from major trials and long-term follow-up of large diabetes treatment studies have sparked a lot of discussion about how low to try and push hemoglobin A1c levels in people with diabetes. Clinicians may be wondering whether intensive glucose control is safe and worth the effort, and in which patients, after tasting the alphabet soup of  recent findings — from the 10-year follow-up of the UKPDS to the ACCORD and ADVANCE studies, the VADT, and Steno-2, plus the 2009 joint statement on all this from the American Diabetes Association, American Heart Assocation, and American College of Cardiology.

Dr. Elizabeth Murphy, chief of endocrinology at San Francisco General Hospital, put it all in perspective. What to do differently? Not much. Aim for a hemoglobin A1c level below 7% for most patients. Consider lower targets for younger, healthier, newly diagnosed patients. Consider higher targets if the patient is expected to live less than 5 years, or has severe hypoglycemia, advanced complications, or other significant comorbid conditions. The American Association of Clinical Endocrinologists still recommends A1c targets below 6.5%, she added.

At conferences like this, spoon-feeding the blood sugar data helps the medicine go down…

— Sherry Boschert
Bookmark and Share

Leave a comment

Filed under Endocrinology, Diabetes, and Metabolism, Family Medicine, Internal Medicine